PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis by Travaglino, A et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology 231 (2018) 104–110Review article
PTEN as a predictive marker of response to conservative treatment in
endometrial hyperplasia and early endometrial cancer. A systematic
review and meta-analysis
Antonio Travaglinoa, Antonio Raffoneb,*, Gabriele Sacconeb, Luigi Insabatoa,
Antonio Mollob, Giuseppe De Placidob, Fulvio Zullob
aAnatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy
bGynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II,
Naples, Italy
A R T I C L E I N F O
Article history:
Received 26 July 2018
Received in revised form 6 October 2018
Accepted 8 October 2018
Available online xxx
Keywords:
Immunohistochemistry
Fertility-sparing
LNG-IUD
Endometrial intraepithelial neoplasia
Progestin
Progesterone resistance
Phosphatase and tensin homolog
A B S T R A C T
Objective: Several markers have been studied to predict the responsiveness of endometrial hyperplasia
(EH) and early endometrial cancer (EEC) to progestin therapy. PTEN has played a major role in this ﬁeld,
although its predictive signiﬁcance is still undeﬁned. We aimed to assess if loss of PTEN expression on
pre-treatment endometrial specimen may be a predictive markers of response to progestins in EH and
EEC.
Study Design: MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID and Cochrane Library
were searched for relevant articles from the inception to May 2018. All studies assessing PTEN expression
as predictive marker in EH and EEC treated with progestin were included. Relative risk (RR) for therapy
failure was calculated with 95% conﬁdence interval (CI) and a signiﬁcant p-value<0.05, with a subgroup
analysis based on the histologic category (EEC or EH) and the administration route of progestin (oral or
intrauterine).
Results: Seven cohort studies assessing 376 patients were included. PTEN loss was not signiﬁcantly
associated with the outcome of therapy in the overall analysis (RR = 1.24, 95% CI, 0.88–1.76, p = 0.21),
in + the subgroups of EEC (RR = 0.89, 0.32–2.49, p = 0.83), EH (RR = 1.30, 0.90–1.87 p = 0.16), oral progestin
(RR = 1.25 0.88–1.79, p = 0.22) and intrauterine device (RR = 1.02, 0.36–2.87, p = 0.97).
Conclusion: PTEN seems not to be useful as predictive marker of response to the conservative treatment of
EH and EC, regardless of the administration route (oral or intrauterine) of progestins. We advise future
researcher not to further assess PTEN as a stand-alone predictive marker.
© 2018 Elsevier B.V. All rights reserved.
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Endometrial cancer is the most common gynecologic malig-
nancy in the Western world [1]. In over 80% of cases, it is preceded
by endometrial hyperplasia (EH), an irregular proliferation of
endometrial glands [2,3]. Incidence of EH is about 132/100.000
among women [4].
The revised 2014 WHO classiﬁcation recognizes two types of EH
based on the presence of cytologic atypia: EH without atypia
(benign) and atypical EH (premalignant) [3]. The 20-year-risk of
progression of EH without atypia to cancer is less than 5% [5], thus
it may be managed with observation alone and follow-up biopsies.
On the other hand, atypical EH requires a total hysterectomy, due to
a risk of progression of 29% [5]. Progestins constitute the treatment
of choice for symptomatic EH without atypia and for women with
atypical EH who wish to preserve their fertility or who are not
suitable for surgery [6]. Progestins may still be used for fertility-
sparing treatment of endometrioid type, stage FIGO IA, well-
differentiated early endometrial cancer (EEC) without tumor
invasion of myometrium [7]. Progestins can be administered
orally or through intrauterine device (levonorgestrel-releasing
intrauterine device, LNG-IUD) [6,8].
However, despite progestins’ effectiveness, a variable percent-
age of EH and EEC do not respond to therapy, or even progress to
invasive disease [8].
This has led to a growing interest in searching for predictive
markers of response to progestins on endometrial specimens, in
order to avoid the risk of disease progression linked to an
ineffective therapy. In particular, a major role has been played by
immunohistochemistry, which is the most widely used tool in this
ﬁeld [9].
The tumor suppressor protein phosphatase and tensin homolog
(PTEN) has been one of the most important markers studied in this
ﬁeld, due to its recognized role in endometrial carcinogenesis [2]. A
prognostic signiﬁcance of PTEN expression in EH has already been
reported for the risk of concurrent cancer [10] and progression to
cancer [11]. Some authors also suggested a role of PTEN in
resistance to progestins [12,13], although this point has not yet
been clariﬁed.
Thus, the aim of this systematic review and meta-analysis was
to assess if immunohistochemical loss of PTEN expression on pre-
treatment endometrial specimen may be a predictive marker of
response to progestins in EH and EEC.
Materials and methods
Study protocol
This study was performed according to a protocol recom-
mended for systematic review and meta-analysis. The protocol
deﬁning methods for collecting, extracting and analyzing data was
designed a priori. All review stages were conducted independently
by two reviewers (AT and AR) and disagreements were resolved by
discussion with a third author (GS).Search strategy
Several researches were conducted using MEDLINE, EMBASE,
Web of Sciences, Scopus, ClinicalTrial.gov, OVID and Cochrane
Library as electronic databases. The studies were identiﬁed by
using a combination of the following text words from the
inception to May 2018: endometrial hyperplasia; endometrial
cancer; endometrioid adenocarcinoma; endometrial intraepithe-
lial neoplasia; EIN; therapy; treatment; fertility sparing; conser-
vative; medroxyprogesterone; MPA; mirena; LNG;
levonorgestrel; progestogen; progestin; response; resistance;
persistence; outcome; PTEN; phosphatase and tensin homolog;
marker; immunohistochemistry; immunohistochemical. Review
of articles also included the abstracts of all references retrieved
from the search.
Study selection
We included in our systematic review all randomized and non-
randomized studies that satisﬁed the following inclusion criteria:
 study population constituted by women diagnosed with EH or
EEC and conservatively treated with progestogens;
 assessment of the expression of PTEN on pre-treatment
endometrial specimens by immunohistochemistry;
 assessment of the association between PTEN expression
(presence vs loss) and the response to therapy (good vs poor,
where ‘good response’ denoted a complete regression of EH or
EEC);
 comparability of data.
Risk of bias assessment
According to the Methodological Index for Non-Randomized
Studies (MINORS) [14], six domains related to risk of bias were
assessed in each study: 1) Aim (i.e. clearly stated aim), 2) Rate (i.e.
inclusion of consecutive patients), 3) Data (i.e. prospective
collection of data), 4) Bias (i.e. unbiased assessment of study
endpoints), 5) Time (i.e. follow-up time appropriate), 6) Loss (i.e.
loss to follow-up). Review authors’ judgments were categorized as
“low risk,” “high risk” or “unclear risk of bias.”
Data extraction
Data were extracted from each study without modiﬁcation.
Two by twocontingency tables were prepared reporting two
dichotomous qualitative variables: PTEN expression on pre-
treatment biopsy (“presence” vs “loss”) and response to conserva-
tive therapy (“good” vs “poor”, where “good response” indicated a
complete regression of disease). When discrepancies between text
and tables were found, values from tables were used. In one study
[15], 2 women treated with LNG-IUD showed no overt ﬁndings of
EH on follow-up biopsy, although PTEN-null glands were still
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according to Mutter et al the presence of PTEN-null glands would
indicate a latent precancer [16] and thus not a complete regression.
Data were also subdivided into subgroups based on the
histologic diagnosis (EH or EEC) and administration route of
progestins (oral or intrauterine).
Data analysis
The impact of PTEN status on the therapy outcome was assessed
as relative risk (RR) for failure of therapy, with 95% conﬁdence
interval (CI). RR was calculated for each study and as pooled
estimate and reported graphically on a forest plot. A p-value<0.05
was considered signiﬁcant.
The inconsistency index (I2) was used for the assessment of
statistical heterogeneity among studies: heterogeneity was
considered insigniﬁcant for I2<25%, low for I2<50%, moderate
for I2<75% and high for I275%. In case of I250% a random effect
model was used; in case of I2<50% a ﬁxed effect model was
adopted.
A subgroup analysis was also performed (EH vs EEC; oral vs
intrauterine progestins).
Data analysis was performed using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Centre, Cochrane Collabora-
tion, 2014).
Results
Selection and characteristics of the studies
The process of study selection is summarized in Fig. 1.
Seven studies assessing 376 patients were included
[12,13,15,17–20]. Five studies were retrospective and 2 were
prospective. The sample size ranged from 9 to 141.
Out of 376 EH, 217 had PTEN loss and 159 had PTEN presence at
immunohistochemistry. Patients with good response were 275,
while 101 had poor response. Patients age ranged from 19 to 79.Fig. 1. Flow diagram of studies identiﬁed in the systematic review (Prisma template
[Preferred Reporting Item for Systematic Reviews and Meta-analyses]).Patients BMI ranged from 20 to 39. Histologic diagnosis included
239 non-atypical EH, 98 atypical EH and 39 EEC.
Progestins used included megestrol acetate (N = 65), norethindrone
acetate (N = 14), medroxyprogesterone acetate (N = 207) administered
orally, LNG-IUD (N = 84) or a mixture of more than one progestin (N = 9).
Follow-up duration ranged from 1 to 26 months.
Characteristics of the included studies are shown in Table 1.
Risk of bias assessment
For the “aim” domain, all studies were categorized at low risk of
bias, since they had a clearly stated aim.
For the “rate” domain, three studies were categorized at low
risk, because they selected consecutive patients; the other 4
studies did not clearly specify this point, although it seems that
they included all eligible patients in the period considered, thus
they were considered at unclear risk.
For the “data” domain, 3 studies were categorized at low risk, since
theycollecteddataprospectively;theother4studieswereconsideredat
unclear risk because this information was not speciﬁed.
For the “bias” domain, only one study was categorized at
unclear risk, because it considered non-atypical EH as a regression
of atypical EH; the other 6 studies were considered at low risk, as a
diagnosis complete response implied that no lesions had persisted
at follow-up.
For the “time” domain, 4 studies were categorized at low risk,
since they treated all patients at least for 6 months, as
recommended by guidelines [6,7]; for the other studies the risk
was unclear because the duration of therapy was 1–6 months.
For the “loss” domain, all studies were categorized at unclear
risk, because the number of patients lost to follow-up was not
speciﬁed.
Results of risk of bias assessment are shown in Fig. 2.
PTEN and therapy response
A loss of PTEN expression showed a relative risk for therapy
failure of 1.24 (95% CI, 0.88–1.76); the impact on the risk was not
signiﬁcant (p = 0.21); there was no heterogeneity among studies
(I2 = 0%) (Fig. 3).
In the subgroup of patients with EC (N = 39), RR was 0.89 (95%
CI, 0.32–2.49), without signiﬁcant impact on the therapy outcome
(p = 0.83) and without heterogeneity (I2 = 0%). In the subgroup of
patients with EH (N = 337), RR was 1.30 (95% CI, 0.90–1.87) without
statistical signiﬁcance (p = 0.16) and without signiﬁcant heteroge-
neity (I2 = 16%). There was no signiﬁcant difference between the
two subgroup (Chi2 = 0.45; p = 0.50) (Fig. 3).
On the basis of the treatment administered, the subgroup
treated with oral progestin (N = 291) showed a non-signiﬁcant RR
of 1.25 (95% CI, 0.88–1.79, p = 0.22) with no heterogeneity (I2 = 0%).
In the subgroup treated with LNG-IUD (N = 85), RR was 1.02 (95% CI,
0.36–2.87) without statistical signiﬁcance (p = 0.97) and without
heterogeneity (I2 = 0). There was no signiﬁcant difference between
the two subgroup (Chi2 = 0.14; p = 0.71) (Fig. 4).
Comment
Our results showed that the loss of PTEN expression, evaluated
at immunohistochemistry, does not affect the outcome of
progestin-based therapy of EH and EC.
PTEN gene is a tumor-suppressor gene, located at chromosome
10q23. It encodes a protein with a lipid phosphatase activity, which
induces cell cycle arrest, and favors apoptosis upregulating AKT-
dependent mechanisms and downregulating Bcl-2-dependent
mechanisms, acting in opposition to PI3K. PTEN product has also
a protein phosphatase activity, involved in the inhibition of cell
Ta
b
le
1
C
h
ar
ac
te
ri
st
ic
s
of
th
e
in
cl
u
d
ed
st
u
d
ie
s.
Y
EA
R
FI
R
ST
A
U
TH
O
R
C
O
U
N
TR
Y
ST
U
D
Y
D
ES
IG
N
PE
R
IO
D
O
F
EN
R
O
LL
M
EN
T
SA
M
PL
E
SI
ZE
PA
TI
EN
TS
’
FE
A
TU
R
ES
SA
M
PL
IN
G
M
ET
H
O
D
H
IS
TO
LO
G
Y
PR
O
G
ES
TO
G
EN
A
D
M
IN
IS
TE
R
ED
TR
EA
TM
EN
T
D
U
R
A
TI
O
N
R
ES
PO
N
SE
A
G
E
B
M
I
N
A
H
A
H
EC
M
G
A
N
ET
A
M
PA
LN
G
M
IX
G
O
O
D
PO
O
R
20
07
M
in
ag
u
ch
i
Ja
p
an
re
tr
os
p
ec
ti
ve
19
89
-2
0
03
31
19
-6
0
n
.r.
cu
re
tt
ag
e
–
12
19
–
–
31
–
–
2-
18
m
on
th
s
26
5
20
07
Ya
m
az
aw
a
Ja
p
an
p
ro
sp
ec
ti
ve
19
99
-2
0
05
9
28
-4
0
n
.r.
cu
re
tt
ag
e
–
–
9
–
–
9
–
–
6-
9
m
on
th
s
7
2
20
08
M
il
am
U
SA
re
tr
os
p
ec
ti
ve
n
.r.
38
20
-7
9
n
.r.
bi
op
sy
13
25
–
18
5
16
–
–
1-
12
m
on
th
s
16
22
20
10
A
ke
ss
on
U
K
p
ro
sp
ec
ti
ve
19
99
-2
0
04
34
36
-7
7
21
-4
9
n
.r.
29
5
–
–
–
–
34
–
26
m
on
th
s
28
6
20
12
U
p
so
n
U
SA
re
tr
os
p
ec
ti
ve
19
85
-2
0
05
11
2
<
39
to
>
70
<
25
to
>
30
n
.r.
72
40
–
46
9
50
–
9
n
s
80
32
20
15
O
rb
o
N
or
w
ay
re
tr
os
p
ec
ti
ve
20
05
-2
01
1
14
1
<
4
4
to
>
52
<
20
to
>
30
Pi
p
el
le
12
5
16
–
–
–
93
48
–
6
m
on
th
s
11
2
29
20
16
V
an
G
en
t
N
et
h
er
la
n
d
s
re
tr
os
p
ec
ti
ve
20
02
-2
01
2
11
27
-3
8
20
-3
9
bi
op
sy
,c
u
re
tt
ag
e
–
–
11
1
–
8
2
–
6-
19
m
on
th
s
6
5
TO
TA
L
2
p
ro
sp
ec
ti
ve
5
re
tr
os
p
ec
ti
ve
19
85
-2
01
2
37
6
19
-7
9
20
-3
9
–
23
9
98
39
65
14
20
7
84
9
1-
26
m
on
th
s
27
5
10
1
N
A
H
:n
on
-a
ty
p
ic
al
hy
p
er
p
la
si
a;
A
H
:a
ty
p
ic
al
hy
p
er
p
la
si
a;
E
C
:e
n
d
om
et
ri
al
ca
n
ce
r;
M
G
A
:m
eg
es
tr
ol
ac
et
at
e;
N
E
TA
:n
or
et
h
in
d
ro
n
e
ac
et
at
e;
M
PA
:
m
ed
ro
xy
p
ro
ge
st
er
on
e
ac
et
at
e;
LN
G
:l
ev
on
or
ge
st
re
l-
re
le
as
in
g
in
tr
au
te
ri
n
e
d
ev
ic
e;
M
IX
:
m
ix
tu
re
of
m
or
e
th
an
on
e
p
ro
ge
st
in
;
n
.r
.:
n
ot
re
p
or
te
d
.
Fig. 2. Assessment of risk of bias. Summary of risk of bias for each study; Plus sign:
low risk of bias; minus sign: high risk of bias; question mark: unclear risk of bias.
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MAPK signaling [21].
PTEN has played a major role in the study of endometrial
carcinogenesis, since PTEN gene is the most commonly mutated in
endometrioid carcinoma [22].
In particular, PTEN has been studied as the main marker of
endometrial precancerous lesion; Mutter et al. indeed reported
that PTEN loss at immunohistochemistry might differentiate
premalignant EH from benign functional EH [16,23].
In 2013, the Cancer Genome Atlas Research Network identiﬁed
four distinct molecular categories of EC. In the categories ‘ultra-
mutated’, ‘hypermutated’ and ‘copy number low’, which are typically
endometrioid, PTEN mutations were found in 94%, 88% and 77%
respectively. In the last category (‘copy number high’), mainly
constituted by serous EC, PTEN mutations were found only in 15%
of specimens [22].
A loss of PTEN expression was found to be prognostic for
progression of EH to EC [11], and for the presence of a coexistent EC
after a diagnosis of EH [10]. Given the widespread use of
conservative therapy of EH and EC, great importance has been
given to the search for predictive markers of response [24–27].
PTEN has still played a major role in this ﬁeld, although results
about its predictive ability appear contrasting [12,13,15,17–20].
Fig. 3. PTEN loss in predicting the response to therapy in endometrial hyperplasia and early endometrial cancer. Forest plots report graphically the relative risk for therapy
failure according to the histologic diagnosis (endometrial hyperplasia vs endometrial cancer).
Fig. 4. PTEN loss in predicting the response to therapy in endometrial hyperplasia and early endometrial cancer. Forest plots report graphically the relative risk for therapy
failure according to the type of progestin administered (oral vs intrauterine).
108 A. Travaglino et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 231 (2018) 104–110In patients with EC, we found that PTEN loss was associated
with good response to progestins (RR = 0.89), although not
signiﬁcantly (p = 0.83). In this regard, a recent study showed that
PTEN loss at immunohistochemistry did not inﬂuence the
prognosis in EC [29].
In the subgroup of EH, PTEN loss showed a RR of 1.30, which
indicates a negative impact on the response to therapy, although
still without statistical signiﬁcance (p = 0.16). Since PTEN loss in EH
was shown to be predictive for the risk of cancer [10,11], it is
possible that a minor inﬂuence on the response may exist.Even when assessed separately in women treated with oral
progestins and LNG-IUD, the predictive value of PTEN loss was
never signiﬁcant.
Anyway, while the statistical signiﬁcance might be achieved by
assessing a larger sample, the impact on the response to therapy
would still appear insufﬁcient to have a bearing on the patient
management, due to the low values of RR observed. Conservative
management of atypical EH and EEC is not indeed the standard
treatment, and the risk of progression to invasive disease is already
taken into account, so patients undergo a close follow-up. Being
A. Travaglino et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 231 (2018) 104–110 109the regression rates reported for LNG-IUD over 90% [8], a predictive
marker should increase the risk of failure at least 3–4 folds to have
a clinical signiﬁcance.
All these results indicate that PTEN immunohistochemical
status does not signiﬁcantly impact on the response to progestins
in EH and EC. Thus, further studies in this ﬁeld should no more
assess PTEN as a stand-alone predictive marker.
In this regard, two studies among those included in our review
suggested a possible predictive role for PTEN if assessed together
with other molecules. In particular, Minaguchi et al. reported that
the presence of at least one between PTEN loss and low expression
of phospho-AKT was associated with higher therapy failure,
compared to the absence of both [12]. Milam et al. showed that
a decreased PTEN expression accompanied by a phospho-mTOR
overexpression on the follow-up biopsy is associated with a poor
response [13]. Remarkably, both phospho-AKT and phospho-mTOR
are molecules involved in the same pathway as PTEN [12,13].
Nonetheless, evidence in this ﬁeld it is weak and it is unclear which
signiﬁcance these ﬁndings may have in the patient management.
Several other predictive markers have been assessed by immuno-
histochemistry in EH and EC. Among these, estrogen and
progesterone receptors have shown association with good
response to progestins in some studies [17–19]. By contrast, other
studies showed opposite results [12,24], and European guidelines
discourage their use [7]. One study showed that deﬁcient
expression of mismatch repair proteins was predictive of poor
response, with perfect speciﬁcity [27]; however, given some
limitations inherent to the study population, this result need to be
further conﬁrmed [28].
With the recent progresses about the molecular deﬁnition of
endometrial neoplastic specimens [22,29,30], in the near future
the role of such molecules might be clariﬁed.
Strengths and limitation
To the best of our knowledge, this is the ﬁrst review assessing
the role of PTEN in the conservative management of EH and EEC.
Our study clariﬁed that immunohistochemical expression of PTEN
does not affect the outcome of progestin-therapy in EH and EC,
independently from histologic category or type of progestin
administered.
A limitation of our study might be the relatively small size of the
sample assessed (N = 376), although the absence of heterogeneity
among studies (I2 = 0%) and the constancy of RR values in the
several groups give solidity to our results. Furthermore, we
considered PTEN expression assessed by only immunohistochem-
istry. Several concerns with PTEN immunohistochemistry have
been reported, such as subjectivity in the interpretation of
immunostaining and lack of a standard protocol [31]. On the
other hand, immunohistochemistry allows evaluating both inten-
sity and distribution of the marker expression. There is evidence
that PTEN immunohistochemistry may outperform PTEN gene
sequencing [32]. For our analysis, we took into account only a
complete loss of immunostaining, which should be easily readable
even without expertise in immunohistochemistry. Anyway, to the
best of our knowledge, there are no studies evaluating the
predictive value of PTEN by techniques other than immunohis-
tochemistry in patients with EH and/or EC treated with progestins
progestin. Two studies assessed the association between PTEN
mRNA and progesterone receptor expression, showing conﬂicting
results [33,34]. However, studies demonstrating associations
between PTEN and progesterone receptor expression may have
limited value, as the expression of progesterone receptor seems to
not reliably reﬂect the responsiveness to progestins [7].
Another limitation may be the absence of studies treating
patients by hysteroscopic resection plus progestin, which hasrecently been described as the most effective conservative
treatment for EH and EC [35,36].
Finally, we were unable to extract data separately for atypical
and non-atypical EH.
Conclusion
Loss of PTEN expression seems not to be useful as predictive
marker of response to progestins in EH and EEC, regardless of the
administration route (oral or intrauterine). We advise future
researcher not to further assess PTEN as a stand-alone predictive
marker. However, the combined assessment of PTEN with other
markers might have a predictive utility, but further evidence is
required in this regard.
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